[SCHEDULE 13G/A] Sweetgreen, Inc. SEC Filing
FMR LLC (parent holding company for Fidelity) and its controlling person Abigail P. Johnson filed Amendment No. 9 to Schedule 13G on 08 Aug 2025 for Taysha Gene Therapies Inc. (TSHA).
- Beneficial ownership: 15,627,821.87 common shares, representing 6.2 % of the outstanding class as of 30 Jun 2025.
- Control rights: Sole voting power over 15,622,332 shares and sole dispositive power over the full 15.628 million; no shared voting or dispositive authority is reported.
- Filing status: Report made under Rule 13d-1(b) as a parent holding company/HC; ownership is held in the ordinary course of business without intent to influence control.
- The amendment keeps FMR above the 5 % reporting threshold, signalling continued material institutional exposure to TSHA.
FMR LLC (societ脿 madre di Fidelity) e la sua persona di controllo Abigail P. Johnson hanno presentato il Modifica n. 9 al Schedule 13G l'08 agosto 2025 per Taysha Gene Therapies Inc. (TSHA).
- Propriet脿 effettiva: 15.627.821,87 azioni ordinarie, rappresentanti il 6,2% della classe in circolazione al 30 giugno 2025.
- Diritti di controllo: Potere di voto esclusivo su 15.622.332 azioni e potere dispositive esclusivo sull'intero ammontare di 15,628 milioni; non sono segnalati poteri di voto o dispositivi condivisi.
- Stato della dichiarazione: Segnalazione effettuata ai sensi della Regola 13d-1(b) come societ脿 madre/holding company; la propriet脿 猫 detenuta nell'ordinaria attivit脿 commerciale senza intento di influenzare il controllo.
- La modifica mantiene FMR sopra la soglia di segnalazione del 5%, indicando una continua esposizione istituzionale significativa su TSHA.
FMR LLC (compa帽铆a matriz de Fidelity) y su persona de control Abigail P. Johnson presentaron la Enmienda No. 9 al Schedule 13G el 8 de agosto de 2025 para Taysha Gene Therapies Inc. (TSHA).
- Propiedad beneficiaria: 15.627.821,87 acciones comunes, que representan el 6,2% de la clase en circulaci贸n al 30 de junio de 2025.
- Derechos de control: Poder exclusivo de voto sobre 15.622.332 acciones y poder exclusivo dispositive sobre el total de 15,628 millones; no se reporta autoridad compartida de voto o dispositiva.
- Estado de la presentaci贸n: Informe presentado bajo la Regla 13d-1(b) como compa帽铆a matriz/holding; la propiedad se mantiene en el curso ordinario del negocio sin intenci贸n de influir en el control.
- La enmienda mantiene a FMR por encima del umbral de reporte del 5%, se帽alando una exposici贸n institucional material continua a TSHA.
FMR LLC(Fidelity鞚� 氇殞靷�)鞕� 攴� 韱奠牅鞚鸽鞚� Abigail P. Johnson鞚� 2025雲� 8鞗� 8鞚检棎 Taysha Gene Therapies Inc. (TSHA)鞐� 雽�頃� Schedule 13G 9彀� 靾橃爼靹�毳� 鞝滌稖頄堨姷雼堧嫟.
- 鞁れ 靻岇湢: 15,627,821.87 氤错喌欤茧, 2025雲� 6鞗� 30鞚� 旮办 鞝勳泊 氚滍枆 欤检嫕鞚� 6.2%鞐� 頃措嫻頃╇媹雼�.
- 韱奠牅 甓岉暅: 15,622,332欤检棎 雽�頃� 雼弲 鞚橁舶甓岅臣 鞝勳泊 1,562毵� 8觳� 欤检棎 雽�頃� 雼弲 觳橂秳甓岇潉 氤挫湢頃橂┌, 瓿奠湢霅� 鞚橁舶甓岇澊雮� 觳橂秳甓岇潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
- 鞁犼碃 靸來儨: Rule 13d-1(b)鞐� 霐半澕 氇殞靷�/歆赌欤柬殞靷�搿� 鞁犼碃霅橃棃鞙茧┌, 靻岇湢甓岇潃 瓴届榿 頇滊彊鞚� 鞚柬櫂鞙茧 氤挫湢霅橃柎 韱奠牅甓� 頄夓偓 鞚橂弰電� 鞐嗢姷雼堧嫟.
- 鞚措矆 靾橃爼鞙茧 FMR鞚� 5% 氤搓碃 旮办靹犾潉 鞙犾頃橂┌, TSHA鞐� 雽�頃� 欷戩殧頃� 旮瓣磤 韴瀽 雲胳稖鞚� 瓿勳啀霅潉 雮橅儉雰呺媹雼�.
FMR LLC (soci茅t茅 m猫re de Fidelity) et sa personne contr么lante Abigail P. Johnson ont d茅pos茅 l'Amendement n掳9 au Schedule 13G le 8 ao没t 2025 pour Taysha Gene Therapies Inc. (TSHA).
- Propri茅t茅 b茅n茅ficiaire : 15 627 821,87 actions ordinaires, repr茅sentant 6,2 % de la classe en circulation au 30 juin 2025.
- Droits de contr么le : Pouvoir de vote exclusif sur 15 622 332 actions et pouvoir exclusif de disposition sur l'int茅gralit茅 des 15,628 millions ; aucun pouvoir de vote ou de disposition partag茅 n'est d茅clar茅.
- Statut du d茅p么t : D茅claration effectu茅e en vertu de la r猫gle 13d-1(b) en tant que soci茅t茅 m猫re/holding ; la propri茅t茅 est d茅tenue dans le cours normal des affaires sans intention d'influencer le contr么le.
- L'amendement maintient FMR au-dessus du seuil de d茅claration de 5 %, indiquant une exposition institutionnelle significative continue 脿 TSHA.
FMR LLC (Muttergesellschaft von Fidelity) und deren kontrollierende Person Abigail P. Johnson reichten am 8. August 2025 die 脛nderung Nr. 9 zum Schedule 13G 蹿眉谤 Taysha Gene Therapies Inc. (TSHA) ein.
- Wirtschaftliches Eigentum: 15.627.821,87 Stammaktien, was 6,2 % der ausstehenden Klasse zum 30. Juni 2025 entspricht.
- Kontrollrechte: Alleiniges Stimmrecht 眉ber 15.622.332 Aktien und alleiniges Verf眉gungsrecht 眉ber die gesamten 15,628 Millionen; keine geteilten Stimm- oder Verf眉gungsrechte gemeldet.
- Meldestatus: Meldung gem盲脽 Regel 13d-1(b) als Muttergesellschaft/Holding; Eigentum wird im normalen Gesch盲ftsverlauf gehalten ohne Absicht, die Kontrolle zu beeinflussen.
- Die 脛nderung h盲lt FMR 眉ber der 5 %-Meldegrenze, was auf eine weiterhin wesentliche institutionelle Beteiligung an TSHA hinweist.
- FMR LLC retains a sizable 6.2 % stake, reflecting ongoing institutional confidence in TSHA.
- Sole voting and dispositive authority give the holder flexibility, indicating high conviction.
- None.
Insights
TL;DR: Fidelity still owns 6.2 % of TSHA, signalling sustained institutional support; impact neutral-to-positive.
FMR鈥檚 15.6 M-share stake confirms that one of the world鈥檚 largest asset managers retains a meaningful position in TSHA. While the filing doesn鈥檛 disclose whether the position was raised or trimmed, remaining above the 5 % threshold often underpins liquidity and can reduce free-float volatility. Sole voting and dispositive power allow Fidelity to act quickly on corporate actions, but its 13G (rather than 13D) status indicates passive intent. For investors, the disclosure is supportive but not transformative; fundamentals and clinical progress still dominate the equity story.
TL;DR: Passive 6.2 % holding gives Fidelity influence without activism; governance risk unchanged.
Because FMR files on Schedule 13G, it affirms no immediate plan to influence TSHA鈥檚 strategy or board composition. Nonetheless, Fidelity鈥檚 ability to cast 6 % of votes can be pivotal in close proxy matters. The unchanged passive classification limits near-term governance friction, but management must still consider large-holder preferences on capital allocation and executive comp. Overall governance impact is limited and largely status quo.
FMR LLC (societ脿 madre di Fidelity) e la sua persona di controllo Abigail P. Johnson hanno presentato il Modifica n. 9 al Schedule 13G l'08 agosto 2025 per Taysha Gene Therapies Inc. (TSHA).
- Propriet脿 effettiva: 15.627.821,87 azioni ordinarie, rappresentanti il 6,2% della classe in circolazione al 30 giugno 2025.
- Diritti di controllo: Potere di voto esclusivo su 15.622.332 azioni e potere dispositive esclusivo sull'intero ammontare di 15,628 milioni; non sono segnalati poteri di voto o dispositivi condivisi.
- Stato della dichiarazione: Segnalazione effettuata ai sensi della Regola 13d-1(b) come societ脿 madre/holding company; la propriet脿 猫 detenuta nell'ordinaria attivit脿 commerciale senza intento di influenzare il controllo.
- La modifica mantiene FMR sopra la soglia di segnalazione del 5%, indicando una continua esposizione istituzionale significativa su TSHA.
FMR LLC (compa帽铆a matriz de Fidelity) y su persona de control Abigail P. Johnson presentaron la Enmienda No. 9 al Schedule 13G el 8 de agosto de 2025 para Taysha Gene Therapies Inc. (TSHA).
- Propiedad beneficiaria: 15.627.821,87 acciones comunes, que representan el 6,2% de la clase en circulaci贸n al 30 de junio de 2025.
- Derechos de control: Poder exclusivo de voto sobre 15.622.332 acciones y poder exclusivo dispositive sobre el total de 15,628 millones; no se reporta autoridad compartida de voto o dispositiva.
- Estado de la presentaci贸n: Informe presentado bajo la Regla 13d-1(b) como compa帽铆a matriz/holding; la propiedad se mantiene en el curso ordinario del negocio sin intenci贸n de influir en el control.
- La enmienda mantiene a FMR por encima del umbral de reporte del 5%, se帽alando una exposici贸n institucional material continua a TSHA.
FMR LLC(Fidelity鞚� 氇殞靷�)鞕� 攴� 韱奠牅鞚鸽鞚� Abigail P. Johnson鞚� 2025雲� 8鞗� 8鞚检棎 Taysha Gene Therapies Inc. (TSHA)鞐� 雽�頃� Schedule 13G 9彀� 靾橃爼靹�毳� 鞝滌稖頄堨姷雼堧嫟.
- 鞁れ 靻岇湢: 15,627,821.87 氤错喌欤茧, 2025雲� 6鞗� 30鞚� 旮办 鞝勳泊 氚滍枆 欤检嫕鞚� 6.2%鞐� 頃措嫻頃╇媹雼�.
- 韱奠牅 甓岉暅: 15,622,332欤检棎 雽�頃� 雼弲 鞚橁舶甓岅臣 鞝勳泊 1,562毵� 8觳� 欤检棎 雽�頃� 雼弲 觳橂秳甓岇潉 氤挫湢頃橂┌, 瓿奠湢霅� 鞚橁舶甓岇澊雮� 觳橂秳甓岇潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
- 鞁犼碃 靸來儨: Rule 13d-1(b)鞐� 霐半澕 氇殞靷�/歆赌欤柬殞靷�搿� 鞁犼碃霅橃棃鞙茧┌, 靻岇湢甓岇潃 瓴届榿 頇滊彊鞚� 鞚柬櫂鞙茧 氤挫湢霅橃柎 韱奠牅甓� 頄夓偓 鞚橂弰電� 鞐嗢姷雼堧嫟.
- 鞚措矆 靾橃爼鞙茧 FMR鞚� 5% 氤搓碃 旮办靹犾潉 鞙犾頃橂┌, TSHA鞐� 雽�頃� 欷戩殧頃� 旮瓣磤 韴瀽 雲胳稖鞚� 瓿勳啀霅潉 雮橅儉雰呺媹雼�.
FMR LLC (soci茅t茅 m猫re de Fidelity) et sa personne contr么lante Abigail P. Johnson ont d茅pos茅 l'Amendement n掳9 au Schedule 13G le 8 ao没t 2025 pour Taysha Gene Therapies Inc. (TSHA).
- Propri茅t茅 b茅n茅ficiaire : 15 627 821,87 actions ordinaires, repr茅sentant 6,2 % de la classe en circulation au 30 juin 2025.
- Droits de contr么le : Pouvoir de vote exclusif sur 15 622 332 actions et pouvoir exclusif de disposition sur l'int茅gralit茅 des 15,628 millions ; aucun pouvoir de vote ou de disposition partag茅 n'est d茅clar茅.
- Statut du d茅p么t : D茅claration effectu茅e en vertu de la r猫gle 13d-1(b) en tant que soci茅t茅 m猫re/holding ; la propri茅t茅 est d茅tenue dans le cours normal des affaires sans intention d'influencer le contr么le.
- L'amendement maintient FMR au-dessus du seuil de d茅claration de 5 %, indiquant une exposition institutionnelle significative continue 脿 TSHA.
FMR LLC (Muttergesellschaft von Fidelity) und deren kontrollierende Person Abigail P. Johnson reichten am 8. August 2025 die 脛nderung Nr. 9 zum Schedule 13G 蹿眉谤 Taysha Gene Therapies Inc. (TSHA) ein.
- Wirtschaftliches Eigentum: 15.627.821,87 Stammaktien, was 6,2 % der ausstehenden Klasse zum 30. Juni 2025 entspricht.
- Kontrollrechte: Alleiniges Stimmrecht 眉ber 15.622.332 Aktien und alleiniges Verf眉gungsrecht 眉ber die gesamten 15,628 Millionen; keine geteilten Stimm- oder Verf眉gungsrechte gemeldet.
- Meldestatus: Meldung gem盲脽 Regel 13d-1(b) als Muttergesellschaft/Holding; Eigentum wird im normalen Gesch盲ftsverlauf gehalten ohne Absicht, die Kontrolle zu beeinflussen.
- Die 脛nderung h盲lt FMR 眉ber der 5 %-Meldegrenze, was auf eine weiterhin wesentliche institutionelle Beteiligung an TSHA hinweist.
FAQ
How many TSHA shares does FMR LLC currently own?
What percentage of Taysha Gene Therapies鈥� outstanding shares does this represent?
Does FMR LLC have voting control over these shares?
Is Fidelity鈥檚 position considered active or passive?
Who signed the filing on behalf of FMR LLC and Abigail P. Johnson?
